filmov
tv
Regeneron's Dupixent shows promise as COPD treatment
Показать описание
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
#CNBC
#CNBCTV
0:02:30
Dupilumab Could Improve Skin Lesions in Atopic Dermatitis
0:41:42
Leonard S. Schleifer, M.D., Ph.D., Founder and Chief Executive Officer, Regeneron Pharmaceuticals
0:32:46
062 - Treatments from Gilead and Regeneron Move Forward in Battle Against COVID-19!
0:02:11
Eczema Treatment Helping Some Alopecia Sufferers Regrpw Hair
0:02:23
Maine woman fighting COPD for past 15 years waits for lung transplant
0:25:49
Dr. Brian S. Kim presents Stephen Katz Lecture 5_2022
0:27:13
Emma Guttman, MD, PhD - Frontiers In Academic Pathology 2015
0:01:41
Check Your Health COPD Risk Score
1:19:53
10/18/22 JAK Inhibitors vs Biologics for Atopic Dermatitis
1:15:44
Webinar Newly Diagnosed with Atopic Dermatitis? Here's What You Need to Know
0:43:23
Partnerships Leading to a Healthier Tomorrow | Future of Health Summit 2024
0:08:32
How to Treat Chronic Obstructive Pulmonary Disease (COPD) with Samir Makani, MD | San Diego Health
0:56:27
Advances in the Management of Moderate to Severe Atopic Dermatitis
2:18:10
Annual Biotechnology Conference 2020 - Pennsylvania Biotechnology Center (PABC)
0:27:10
Яндекс (интерактивные услуги), Полюс (золото) и Regeneron (биотехнологии) - компании дня на 26.02....
0:07:07
4 latest treatments for COPD! Study Review! Living Healthy with COPD!
1:51:56
NACFC 2023 | S12: Best Practices in GI Care in the Post-Modulator Era
0:08:55
SCCM 2023: 4 Major trials
0:02:59
Natalie L.’s Story – How Believing in Yourself Helps COPD
1:07:19
Webinar: Management Strategies for Eosinophilic Esophagitis (EoE)
0:13:59
9 Top Biotech Stocks To Buy Now 🚀
0:49:53
Creating An Enterprise Grade AI Environment with Sanofi, State Street, Amazon & JP Morgan Chase
0:56:40
2018 Pharma R+D Report Webinar Recording
1:00:35
3/16/21 - “COVID-19 Vaccines, Treatments, and Undervalued Biopharma”
Комментарии